Wun T C, Capuano A
Blood. 1987 May;69(5):1354-62.
The initiation and regulation of fibrinolysis has been studied by reconstitution of fibrinolytic activity in human plasma in vitro. Depletion of tissue plasminogen activator (tPA) antigen by immunoadsorption of human plasma with anti-tPA Ig Sepharose 4B leads to total loss of spontaneous fibrinolytic activity determined by lysis of a thrombin-induced clot. Addition of physiological concentrations of purified tPA to tPA-depleted plasma restores fibrinolytic activity as a function of the length of time between tPA addition and clotting. Addition of free tPA to tPA-depleted plasma followed by immediate clotting results in a high rate of fibrinolysis. In contrast, when free tPA is allowed to incubate in plasma for 10 to 60 minutes prior to clot formation, the fibrinolytic activity of tPA is gradually lost. The loss of tPA-induced fibrinolytic activity in unclotted plasma is accompanied by decreased partitioning of tPA antigen into fibrin after clotting and is kinetically correlated with the formation of a 100 kilodalton (kDa) tPA complex as demonstrated by SDS-gel electrophoresis and fibrin-agar zymography. These results suggest that free tPA is susceptible to complexation by the plasma inhibitor in the absence of a clot. Fibrin formation renders tPA relatively inaccessible to inhibition. The tPA antigen isolated from stored plasma consists mainly of 100 kDa activity in SDS-gel electrophoresis and zymography, indicating that the tPA complex is resistant to dissociation by SDS. Upon rezymography of the sliced gel, only a 60 kDa tPA activity is found, suggesting that the activity at 100 kDa is at least partly due to free tPA dissociated from the complex during the first zymography. Conversion of tPA complex to enzymatically active free tPA also occurs with brief SDS exposure followed by incubation in the presence of excess Triton X-100 or by hydroxylamine treatment. These results reconcile the apparent discrepancy of the 100 kDA inhibitor-tPA complex manifesting plasminogen activation activity during zymography. The plasma tPA-inhibitor complex is precipitated strongly by antisera against plasminogen activator inhibitors (PAIs) of human Hep G2 hepatoma and HT-1080 fibrosarcoma cells and weakly by antiserum against bovine aortic endothelial cell PAI but not by antiserum against a placental PAI (PAI-2) suggesting that the plasma inhibitor is immunologically related to Hep G2, HT-1080 and possibly endothedial cell PAIs. Based on the above findings, a simple model for the initiation and regulation of plasma fibrinolysis at the PA level has been formulated.
通过在体外重组人血浆中的纤溶活性,对纤溶作用的启动和调节进行了研究。用抗tPA Ig Sepharose 4B免疫吸附人血浆,使组织纤溶酶原激活物(tPA)抗原耗竭,导致通过凝血酶诱导的凝块溶解所测定的自发纤溶活性完全丧失。向tPA耗竭的血浆中添加生理浓度的纯化tPA,可恢复纤溶活性,其是添加tPA与凝血之间时间长度的函数。向tPA耗竭的血浆中添加游离tPA后立即凝血,会导致高纤溶速率。相反,当在凝块形成前让游离tPA在血浆中孵育10至60分钟时,tPA的纤溶活性会逐渐丧失。未凝血浆中tPA诱导的纤溶活性丧失伴随着凝血后tPA抗原向纤维蛋白中的分配减少,并且在动力学上与100千道尔顿(kDa)tPA复合物的形成相关,如SDS-凝胶电泳和纤维蛋白-琼脂酶谱法所示。这些结果表明,在没有凝块的情况下,游离tPA易受血浆抑制剂的复合作用影响。纤维蛋白的形成使tPA相对不易被抑制。从储存血浆中分离的tPA抗原在SDS-凝胶电泳和酶谱法中主要由100 kDa活性组成,表明tPA复合物对SDS解离具有抗性。对切片凝胶进行再酶谱分析时,仅发现60 kDa的tPA活性,表明100 kDa处的活性至少部分归因于在第一次酶谱分析期间从复合物中解离的游离tPA。在短暂暴露于SDS后,接着在过量Triton X-100存在下孵育或通过羟胺处理,也会发生tPA复合物向具有酶活性的游离tPA的转化。这些结果解释了在酶谱分析期间100 kDA抑制剂-tPA复合物表现出纤溶酶原激活活性这一明显差异。血浆tPA-抑制剂复合物被针对人Hep G2肝癌细胞和HT-1080纤维肉瘤细胞的纤溶酶原激活物抑制剂(PAIs)的抗血清强烈沉淀,被针对牛主动脉内皮细胞PAI的抗血清弱沉淀,但不被针对胎盘PAI(PAI- 2)的抗血清沉淀,这表明血浆抑制剂在免疫上与Hep G2、HT-1080以及可能的内皮细胞PAIs相关。基于上述发现,已构建了一个在PA水平上血浆纤溶作用启动和调节的简单模型。